Summary
Vertex Pharmaceuticals Inc. (VRTX) filed an 8-K report on June 5, 2019, detailing outcomes from its 2019 annual shareholder meeting. The key events include shareholder approval of amendments to two significant equity-based compensation plans: the 2013 Stock and Option Plan, which will see an increase of 5.0 million shares authorized for issuance, and the Employee Stock Purchase Plan, which will increase by 2.0 million shares authorized for issuance. These approvals are crucial for future employee incentives and stock-based compensation strategies. Additionally, the meeting saw the election of six directors to the board until the 2020 annual meeting, all of whom were elected with substantial support. Shareholders also ratified the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2019. The advisory vote on executive compensation was approved, while two shareholder proposals, one concerning drug pricing risk in executive compensation and another on lobbying activities, did not receive majority approval.
Key Highlights
- 1Shareholders approved amendments to the 2013 Stock and Option Plan, increasing authorized shares by 5.0 million.
- 2Shareholders approved amendments to the Employee Stock Purchase Plan, increasing authorized shares by 2.0 million.
- 3Six directors (Sangeeta Bhatia, Lloyd Carney, Terrence Kearney, Yuchun Lee, Jeffrey Leiden, and Bruce Sachs) were elected to the Board of Directors.
- 4Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2019.
- 5Shareholders approved, on an advisory basis, the compensation program for named executive officers.
- 6Two shareholder proposals, one on drug pricing risk in executive compensation and another on lobbying activities, were not approved by shareholders.